BrightHeart’s B‑Right AI becomes available through GE HealthCare’s Voluson digital marketplace

BrightHeart announced that its B‑Right AI Platform is now available via GE HealthCare’s Voluson Solution Store, putting cloud‑based fetal imaging guidance and automated screening tools directly into a widely used ultrasound ecosystem. The integration is designed to provide real‑time acquisition guidance, quality checks and automated screening for congenital heart disease (CHD) within the Voluson workflow so that clinicians can capture more complete anatomic exams and standardize interpretation across operators and sites. BrightHeart positions the tool as clinically validated to improve detection of fetal cardiac anomalies and to reduce variability related to operator skill and resource constraints. By distributing through Voluson’s digital marketplace, BrightHeart can reach Voluson customers without requiring hardware changes, easing trialing and procurement compared with direct sales. That distribution model mirrors broader sector shifts toward software‑first deployments, recurring pricing and marketplace storefronts that lower barriers to adoption but place a premium on integration, service and evidence generation. The partnership aims to extend advanced screening capabilities to lower‑resourced settings and hub‑and‑spoke teleimaging networks where sonographer shortages produce inconsistent prenatal surveillance. Observers should note the regulatory and commercial context: other fetal‑ultrasound AI vendors have recently advanced through regulatory pathways, underscoring the need for ongoing post‑market surveillance and performance monitoring across diverse devices and populations. Practical risks include reliance on cloud connectivity, local PACS and EHR integration, data governance, and the operational work of clinician training and change management. For health systems, the proposition combines potential operational gains — faster, more complete scans and reduced review burden — with clinical gains from earlier identification of structural issues that influence prenatal management. Payers and hospital procurement teams will likely demand real‑world outcome data and economic models that show downstream value before committing to broad rollouts. Commercially, marketplace listing should accelerate access and pilot deployment, but converting trials into recurring revenue will require robust support, interoperable integrations and demonstrable improvements in care pathways. Ultimately, the initiative reflects an industry move to embed validated AI into established imaging platforms; its long‑term effect will depend on measurable outcomes, scalable IT integration and sustainable commercial models.